Skip to main content

Table 1 Characteristics of participants

From: Long-term platinum retention after treatment with cisplatin and oxaliplatin

  Cisplatin Oxaliplatin
Gender (m/f) 13 m/7 f 20 m/5 f
Age at time of follow-up (median) 49 years 64 years
Duration of follow-up 18–75 months (median 41) 8–33 months (median 18)
Tumour type Testicular carcinoma (9) Colorectal carcinoma (25)
  Yolk sac carcinoma (1)  
  Non small cell lung cancer (1)  
  Small cell lung cancer (1)  
  Head and neck carcinoma (8)  
Cumulative dose 300–600 mg/m2 cisplatin (median 350) 585–1170 mg/m2 oxaliplatin (median 878)
  195–390 mg/m2 Pt 287–575 mg/m2 Pt
  (median 227) (median 431)
Sodium thiosulfate 5 head and neck carcinoma patients treated intra-arterially with 600 mg/m2 cisplatin NA
Ca/Mg infusion NA 24/25
GSTM1 8/20 positive, 12/20 negative 10/25 positive, 15/25 negative
GSTT1 17/20 wildtype, 3/20 negative 21/25 positive, 4/25 negative
GSTP1 12/20105Ile/105Ile-GSTP1 9/25105Ile/105Ile-GSTP1
  7/20105Val/105Ile-GSTP1 10/25105Val/105Ile-GSTP1
  1/20105Val/105Val-GSTP1 6/25105Val/105Val-GSTP1
  1. NA = not applicable